Overview of Challenges With Using Cost-Effectiveness Analysis for Evaluating Medications.

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Health Outcomes Research

Background:

• Universal healthcare systems, like Australia's, routinely conduct cost-effectiveness evaluations for new medications.
• The United States healthcare system largely lacks national-level cost-effectiveness analysis for drugs, with limited exceptions like vaccine evaluations.

Purpose of the Study:

• To provide an overview of the challenges associated with using cost-effectiveness analysis (CEA) for evaluating prescription medications.
• To specifically address these challenges within the context of the United States healthcare system.

Main Methods:

• The paper reviews the principles of cost-effectiveness analysis, including the use of natural units and utility measurements like quality-adjusted life-years (QALYs).
• It discusses inherent challenges in parameter assessment for CEA, focusing on utility values and their impact on individuals with pre-existing health conditions.
• Explores the role of Multiple Criteria Decision Analysis (MCDA) as an alternative or supplementary approach.

Main Results:

• A significant challenge in cost-utility analysis (CUA) is the underestimation of utility values for patients with age-related health issues, disabilities, or comorbidities.
• These utility decrements disproportionately affect vulnerable populations, leading to calls for methodological revisions.
• The absence of a single-payer system in the U.S. exacerbates difficulties in performing comprehensive economic evaluations of medications.

Conclusions:

• Revisions to cost-utility analysis are needed, particularly concerning the accurate characterization of utility values.
• Addressing the challenges of medication economic evaluations in the U.S. requires systemic changes beyond methodological adjustments.
• The Food and Drug Administration (FDA) utilizes Multiple Criteria Decision Analysis (MCDA) to incorporate broader perspectives, but controlling drug costs necessitates system-wide reforms.